Home LiteratureArticle Details
PMID: 26168215 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

The Journal of clinical investigation ·Vol. 125 ·No. 9 ·2015-09-00 ·Pages 3356-64

Marvel D, Gabrilovich DI

Abstract

Our understanding of the role of myeloid-derived suppressor cells (MDSCs) in cancer is becoming increasingly complex. In addition to their eponymous role in suppressing immune responses, they directly support tumor growth, differentiation, and metastasis in a number of ways that are only now beginning to be appreciated. It is because of this increasingly complex role that these cells may become an important factor in the treatment of human cancer. In this Review, we discuss the most pertinent and controversial issues of MDSC biology and their role in promoting cancer progression and highlight how these cells may be used in the clinic, both as prognostic factors and as therapeutic targets.

MeSH Terms
Animals Cell Differentiation/immunology Humans Immunity, Cellular Myeloid Cells/immunology,pathology Neoplasm Metastasis Neoplasms/immunology,pathology Tumor Microenvironment/immunology
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Marvel Douglas
Gabrilovich Dmitry I
References (124)
124 references, click to expand
  1. IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.
    Eur J Immunol. 2010 Dec;40(12):3347-57 PMID: 21110318
  2. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
    PLoS One. 2014;9(2):e87705 PMID: 24498358
  3. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.
    Cancer Immunol Immunother. 2009 Jan;58(1):49-59 PMID: 18446337
  4. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.
    Nat Med. 2007 Jul;13(7):828-35 PMID: 17603493
  5. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression.
    Cancer Immunol Immunother. 2013 Nov;62(11):1745-56 PMID: 24092389
  6. Cell-extrinsic effects of tumor ER stress imprint myeloid dendritic cells and impair CD8⁺ T cell priming.
    PLoS One. 2012;7(12):e51845 PMID: 23272178
  7. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.
    Clin Cancer Res. 2008 Dec 15;14(24):8270-8 PMID: 19088044
  8. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.
    J Immunol. 2009 Jan 1;182(1):240-9 PMID: 19109155
  9. The terminology issue for myeloid-derived suppressor cells.
    Cancer Res. 2007 Jan 1;67(1):425; author reply 426 PMID: 17210725
  10. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.
    Cancer Prev Res (Phila). 2013 Jan;6(1):18-26 PMID: 23248097
  11. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways.
    Immunity. 2014 Dec 18;41(6):947-59 PMID: 25500368
  12. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.
    Cancer Res. 2006 Sep 15;66(18):9299-307 PMID: 16982775
  13. Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.
    Br J Cancer. 2014 Jan 7;110(1):83-93 PMID: 24281006
  14. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45 PMID: 19572148
  15. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.
    Cancer Res. 2005 Dec 15;65(24):11743-51 PMID: 16357187
  16. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function.
    Scand J Gastroenterol. 2011 Feb;46(2):156-64 PMID: 20822377
  17. Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation.
    J Clin Invest. 2011 Jul;121(7):2794-807 PMID: 21646719
  18. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway.
    Cancer Res. 2005 Oct 15;65(20):9525-35 PMID: 16230418
  19. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.
    J Exp Med. 2005 Oct 3;202(7):931-9 PMID: 16186186
  20. TNF signaling drives myeloid-derived suppressor cell accumulation.
    J Clin Invest. 2012 Nov;122(11):4094-104 PMID: 23064360
  21. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
    J Clin Invest. 2014 Jun;124(6):2626-39 PMID: 24789911
  22. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.
    Clin Cancer Res. 2015 Jan 1;21(1):39-48 PMID: 25320361
  23. Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance.
    Sci Signal. 2014 Feb 18;7(313):ra16 PMID: 24550541
  24. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma.
    Clin Cancer Res. 2015 Jan 1;21(1):30-8 PMID: 25564570
  25. Myeloid-derived suppressor cell heterogeneity in human cancers.
    Ann N Y Acad Sci. 2014 Jun;1319:47-65 PMID: 24965257
  26. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
    J Immunol. 2013 Apr 1;190(7):3783-97 PMID: 23440412
  27. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer.
    Blood. 2013 Aug 15;122(7):1105-13 PMID: 23757729
  28. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.
    Clin Cancer Res. 2010 Mar 15;16(6):1812-23 PMID: 20215551
  29. Targeting myeloid regulatory cells in cancer by chemotherapeutic agents.
    Immunol Res. 2011 Aug;50(2-3):276-85 PMID: 21717082
  30. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites.
    Cancer Cell. 2012 May 15;21(5):642-54 PMID: 22624714
  31. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients.
    J Immunother. 2014 Jan;37(1):43-50 PMID: 24316555
  32. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.
    J Clin Invest. 2011 Oct;121(10):4015-29 PMID: 21911941
  33. A two-way interaction between hepatocyte growth factor and interleukin-6 in tissue invasion of lung cancer cell line.
    Am J Respir Cell Mol Biol. 2002 Aug;27(2):220-6 PMID: 12151314
  34. Regulation of dendritic cell differentiation in bone marrow during emergency myelopoiesis.
    J Immunol. 2013 Aug 15;191(4):1916-26 PMID: 23833236
  35. Coordinated regulation of myeloid cells by tumours.
    Nat Rev Immunol. 2012 Apr;12(4):253-68 PMID: 22437938
  36. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
    Am J Respir Crit Care Med. 2012 Nov 15;186(10):1025-36 PMID: 22955317
  37. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.
    Cancer Cell. 2012 Jun 12;21(6):822-35 PMID: 22698406
  38. Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer.
    J Biol Chem. 2013 Jun 28;288(26):19103-15 PMID: 23677993
  39. Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling.
    Cancer Res. 2012 Feb 15;72(4):928-38 PMID: 22237629
  40. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    J Immunol Res. 2014;2014:659294 PMID: 25436215
  41. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.
    Cancer Res. 2006 Jan 15;66(2):1123-31 PMID: 16424049
  42. Origin and pharmacological modulation of tumor-associated regulatory dendritic cells.
    Int J Cancer. 2014 Jun 1;134(11):2633-45 PMID: 24443321
  43. Transmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells.
    Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6561-6 PMID: 21464300
  44. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.
    Immunology. 2013 Feb;138(2):105-15 PMID: 23216602
  45. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.
    J Exp Med. 2010 Oct 25;207(11):2439-53 PMID: 20876310
  46. Complexity and challenges in defining myeloid-derived suppressor cells.
    Cytometry B Clin Cytom. 2015 Mar;88(2):77-91 PMID: 25504825
  47. CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes.
    Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17892-7 PMID: 19815530
  48. Myeloid-derived suppressor cells as regulators of the immune system.
    Nat Rev Immunol. 2009 Mar;9(3):162-74 PMID: 19197294
  49. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.
    Cancer Cell. 2004 Oct;6(4):409-21 PMID: 15488763
  50. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.
    Blood. 2008 Apr 15;111(8):4233-44 PMID: 18272812
  51. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells.
    J Immunol. 2009 Jul 15;183(2):937-44 PMID: 19553533
  52. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche.
    Cancer Cell. 2009 Jan 6;15(1):35-44 PMID: 19111879
  53. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model.
    Breast Cancer Res. 2013;15(5):R79 PMID: 24021059
  54. Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion.
    Eur J Immunol. 2014 Nov;44(11):3307-19 PMID: 25113564
  55. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy.
    Cancer Immunol Immunother. 2015 Jan;64(1):1-13 PMID: 25432147
  56. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer.
    J Clin Invest. 2014 Dec;124(12):5466-80 PMID: 25384214
  57. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
    Eur J Immunol. 2010 Jan;40(1):22-35 PMID: 19941314
  58. The metastasis-promoting roles of tumor-associated immune cells.
    J Mol Med (Berl). 2013 Apr;91(4):411-29 PMID: 23515621
  59. Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
    PLoS One. 2012;7(7):e40677 PMID: 22815789
  60. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.
    Cancer Cell. 2009 Sep 8;16(3):183-94 PMID: 19732719
  61. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice.
    Nat Med. 2014 Jun;20(6):676-81 PMID: 24859530
  62. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.
    J Exp Med. 2006 Nov 27;203(12):2691-702 PMID: 17101732
  63. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer.
    Nat Immunol. 2013 Mar;14(3):211-20 PMID: 23354483
  64. Inhibition of PPARγ in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis.
    Blood. 2012 Jan 5;119(1):115-26 PMID: 22053106
  65. Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells.
    Oncotarget. 2014 Dec 15;5(23):12331-45 PMID: 25514597
  66. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.
    Nature. 2014 Nov 6;515(7525):134-7 PMID: 25156255
  67. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.
    J Exp Med. 2011 Sep 26;208(10):1949-62 PMID: 21930770
  68. Myeloid-derived suppressor cells in the development of lung cancer.
    Cancer Immunol Res. 2014 Jan;2(1):50-8 PMID: 24778162
  69. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.
    Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6742-7 PMID: 19346489
  70. Subsets of myeloid-derived suppressor cells in tumor-bearing mice.
    J Immunol. 2008 Oct 15;181(8):5791-802 PMID: 18832739
  71. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.
    Immunity. 2010 Jun 25;32(6):790-802 PMID: 20605485
  72. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.
    Cancer Res. 2003 Aug 1;63(15):4441-9 PMID: 12907617
  73. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer.
    Innate Immun. 2013 Jun;19(3):328-36 PMID: 23160385
  74. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor.
    PLoS Biol. 2011 Sep;9(9):e1001162 PMID: 21980263
  75. Mapping the crossroads of immune activation and cellular stress response pathways.
    EMBO J. 2013 May 2;32(9):1214-24 PMID: 23584529
  76. CD11b⁺, Ly6G⁺ cells produce type I interferon and exhibit tissue protective properties following peripheral virus infection.
    PLoS Pathog. 2011 Nov;7(11):e1002374 PMID: 22102816
  77. Targeting the interleukin-6/Jak/stat pathway in human malignancies.
    J Clin Oncol. 2012 Mar 20;30(9):1005-14 PMID: 22355058
  78. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.
    J Immunol. 2003 Jan 1;170(1):270-8 PMID: 12496409
  79. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
    Br J Cancer. 2009 Jan 13;100(1):134-44 PMID: 19088723
  80. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.
    J Exp Med. 2014 May 5;211(5):781-90 PMID: 24778419
  81. Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression.
    Cancer Immunol Res. 2013 Jul;1(1):64-76 PMID: 24777249
  82. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma.
    J Immunother. 2010 Oct;33(8):817-27 PMID: 20842055
  83. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
    Cancer Res. 2001 Jun 15;61(12):4756-60 PMID: 11406548
  84. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis.
    Nat Cell Biol. 2006 Dec;8(12):1369-75 PMID: 17128264
  85. Deficiency of Kruppel-like factor KLF4 in myeloid-derived suppressor cells inhibits tumor pulmonary metastasis in mice accompanied by decreased fibrocytes.
    Oncogenesis. 2014 Nov 24;3:e129 PMID: 25417726
  86. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor.
    Blood. 2003 Feb 15;101(4):1316-23 PMID: 12406876
  87. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.
    Cancer Res. 2013 Jan 15;73(2):672-82 PMID: 23243021
  88. Cyclophosphamide-induced suppressor cells in mice: suppression of the antibody response in vitro and characterization of the effector cells.
    Cell Immunol. 1985 Apr 1;91(2):443-54 PMID: 3158396
  89. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
    J Invest Dermatol. 2013 Jun;133(6):1610-9 PMID: 23223128
  90. Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells.
    J Cell Mol Med. 2009 Sep;13(9B):3939-50 PMID: 20196788
  91. Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer.
    Oncotarget. 2014 Nov 30;5(22):11345-53 PMID: 25294811
  92. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.
    J Immunother Cancer. 2013 Jul 15;1:10 PMID: 24829747
  93. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.
    Cancer Res. 2010 May 1;70(9):3526-36 PMID: 20406969
  94. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.
    J Clin Invest. 2013 Oct;123(10):4464-78 PMID: 24091328
  95. Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells.
    J Exp Med. 2015 Mar 9;212(3):351-67 PMID: 25667306
  96. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function.
    Trends Immunol. 2011 Jan;32(1):19-25 PMID: 21067974
  97. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.
    Cancer Res. 2010 Jan 1;70(1):68-77 PMID: 20028852
  98. History of myeloid-derived suppressor cells.
    Nat Rev Cancer. 2013 Oct;13(10):739-52 PMID: 24060865
  99. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
    Int Immunopharmacol. 2009 Jul;9(7-8):900-9 PMID: 19336265
  100. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2.
    Immunity. 2013 Sep 19;39(3):611-21 PMID: 24012420
  101. Can the suppressive activity of myeloid-derived suppressor cells be "chop"ped?
    Immunity. 2014 Sep 18;41(3):341-2 PMID: 25238087
  102. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients.
    J Clin Invest. 2013 Apr;123(4):1580-9 PMID: 23454751
  103. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves.
    J Cancer. 2013;4(1):3-11 PMID: 23386900
  104. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
    Clin Cancer Res. 2005 Sep 15;11(18):6713-21 PMID: 16166452
  105. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
    Clin Cancer Res. 2009 Mar 15;15(6):2148-57 PMID: 19276286
  106. Bone marrow cells in the 'pre-metastatic niche': within bone and beyond.
    Cancer Metastasis Rev. 2006 Dec;25(4):521-9 PMID: 17186383
  107. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.
    J Leukoc Biol. 2012 Jan;91(1):167-81 PMID: 21954284
  108. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
    Cancer Immunol Immunother. 2014 Mar;63(3):247-57 PMID: 24357148
  109. The unfolded protein response: from stress pathway to homeostatic regulation.
    Science. 2011 Nov 25;334(6059):1081-6 PMID: 22116877
  110. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.
    Cancer Res. 2013 Jul 1;73(13):3877-87 PMID: 23633486
  111. Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells.
    Biomed Res. 2009 Feb;30(1):7-15 PMID: 19265258
  112. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Int Immunopharmacol. 2011 Jul;11(7):856-61 PMID: 21315783
  113. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors.
    Immunity. 2014 Sep 18;41(3):389-401 PMID: 25238096
  114. Systemic bacillus Calmette-Guérin (BCG) activates natural suppressor cells.
    Proc Natl Acad Sci U S A. 1978 Oct;75(10):5142-4 PMID: 283421
  115. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
    Cancer Res. 2010 Apr 15;70(8):3052-61 PMID: 20388795
  116. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
    Cancer Metastasis Rev. 2011 Mar;30(1):83-95 PMID: 21249423
  117. Down-regulation of PLCγ2-β-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer.
    J Exp Med. 2013 Oct 21;210(11):2257-71 PMID: 24127488
  118. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen.
    Cell Rep. 2012 Sep 27;2(3):628-39 PMID: 22959433
  119. Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis.
    Mol Cell Proteomics. 2011 Mar;10(3):M110.002980 PMID: 21191032
  120. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
    Cancer Res. 2011 Apr 1;71(7):2664-74 PMID: 21324923
  121. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells.
    Cancer Res. 2014 Oct 15;74(20):5723-33 PMID: 25164013
  122. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.
    Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4185-90 PMID: 15753302
  123. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.
    Cancer Immunol Immunother. 2013 May;62(5):909-18 PMID: 23589106
  124. Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung.
    Cancer Res. 2010 Aug 1;70(15):6139-49 PMID: 20631080
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
1558-8238
DOI
10.1172/JCI80005
Published
2015-09-00
Epub
2015-00-13
Pages
3356-64
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC4588239
Subset
IM
Grants
NCI NIH HHS · P30 CA010815 · United States
NCI NIH HHS · CA 100062 · United States
NCI NIH HHS · R01 CA141438 · United States
NCI NIH HHS · CA 141438 · United States
NCI NIH HHS · R01 CA100062 · United States
NCI NIH HHS · T32 CA009171 · United States
External Links
PubMed source DOI: 10.1172/JCI80005 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2